{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-005889","form_type":"8-K","ticker":null,"cik":"0001840904","company_name":"ATAI Life Sciences N.V.","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.915272+00:00","generated_at":"2026-06-06T08:28:37.501738+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Anne Johnson named CFO of atai Life Sciences; Stephen Bardin departs","bullets":["Stephen Bardin steps down as CFO effective Feb 6, 2024; will advise through March 31, 2024.","Anne Johnson, previously Interim CFO and Chief Accounting Officer, appointed CFO.","Bardin receives severance: 9 months base salary, COBRA, $149,600 bonus, $30,462 parental leave.","Johnson brings ~20 years biopharma experience from Aruvant, Chimerix, PPD, and Xanodyne.","Separation agreement includes release of claims and non-disclosure covenants."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-005889","json":"https://secwatch.observer/filing/0001140361-24-005889.json","markdown":"https://secwatch.observer/filing/0001140361-24-005889.md","text":"https://secwatch.observer/filing/0001140361-24-005889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840904/000114036124005889/0001140361-24-005889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840904/000114036124005889/ef20020799_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T08:28:37.501738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1dda837fab","claim":"Anne Johnson was appointed as Chief Financial Officer at ATAI Life Sciences N.V..","evidence_excerpt":"Effective February 6, 2024, Ms. Johnson was appointed the Company’s Chief Financial Officer, succeeding Mr. Bardin.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036124005889/0001140361-24-005889-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"34a54ebd1f","claim":"Stephen Bardin departed as Chief Financial Officer at ATAI Life Sciences N.V..","evidence_excerpt":"on February 1, 2024, the Company and Mr. Bardin reached an agreement regarding Mr. Bardin’s departure from his position as the Company’s Chief Financial Officer (the “ Separation Agreement ”), effective as of February 6, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840904/000114036124005889/0001140361-24-005889-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}